Living donor liver transplantation (LDLT) is now an established technique for treating children with end-stage liver disease. Few data exist about liver transplantation (LT) for exclusively young infants, especially infants of <3 months of age. We report our single-center experience with 12 patients in which LDLT was performed during the first 3 months of life and compare the results with those of older infants who underwent LT. All of the patients were treated at the National Center of Child Health and Development, Tokyo, Japan. Between November 2005 to November 2016, 436 children underwent LT. Twelve of these patients underwent LT in the first 3 months of life (median age, 41 days; median weight, 4.0 kg). The indications for transplantation were fulminant hepatic failure (n 5 11) and metabolic liver disease (n 5 1). All the patients received the left lateral segment (LLS) in situ to mitigate the problem of graft-to-recipient size discrepancy. A reduced LLS graft was used in 11 patients and a segment 2 monosegment graft was used in 1 patient. We compared the results with those of infants who were 4-6 months of age (n 5 67) and 7-12 months of age (n 5 110) who were treated in the same study period. There were significant differences in the Pediatric End-Stage Liver Disease score and the conversion rate of tacrolimus to cyclosporine in younger infants. Furthermore, the incidence of biliary complications, bloodstream infection, and cytomegalovirus infection tended to be higher, whereas the incidence of acute cellular rejection tended to be lower in younger infants. The overall cumulative 10-year patient and graft survival rates in recipients of <3 months of age were both 90.9%. LDLT during the first 3 months of life appears to be a feasible option with excellent patient and graft survival.
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The scarcity of size-matched pediatric deceased whole liver grafts led to the development of reduced liver transplantation (LT), split LT, and living donor liver transplantation (LDLT). These alternative techniques have expanded the potential donor pool and decreased wait-list mortality in children. The accumulating results of LDLT for children are comparable, even better, to those of cadaveric transplantation (including reduced or split LT) in the countries where the concept of deceased donor LT is not widely accepted. (1) Experience and technical improvements in relation to left-side lobe donation have led to the use of further reducing left lateral segment (LLS) grafts and single segmental or hyper-reduced LLS grafts, in neonatal and infantile LDLT, to overcome the problems associated with large-for-size grafts. (2) (3) (4) The main problems in LT for young infants are the small size of the recipient's abdominal cavity and the insufficient blood supply to the graft, especially in patients without liver cirrhosis, portal hypertension, massive ascites, or hepatomegaly. Segmental grafts (segment 2/3) or reduced LLS (reducing thickness) grafts allow for the potential recipient pool to be expanded to include a greater number of infants, including smaller infants.
Although the indications for LT in young infants (including dominant fulminant hepatic failure [FHF] , hemochromatosis, metabolic disease, etc.) are limited and differ from those in older infants, the rates of morbidity and mortality are considered to be high in comparison to older children because of the technical difficulty and their immunological immaturity. (5) Recently, however, due to these advances in surgical techniques, immunosuppression, and perioperative management, young infants are increasingly listed for LT. (6, 7) LT for young infants is approximately 2% of pediatric LT, and there are much data on infants weighing <5 kg compared with larger infants. (8) (9) (10) (11) (12) At present, however, few data exist about LT for exclusively young infants, especially infants of <3 months of age. (13, 14) We herein report our single-center experience with 12 patients of LDLT that were performed during the first 3 months of life and compare the results with those of older infants who underwent LT. All of the patients were treated at the National Center for Child Health and Development (NCCHD), Tokyo, Japan.
Patients and Methods
Between November 2005 to November 2016, 436 children underwent LT (including 22 patients who underwent deceased liver donor, and 4 who underwent domino LT) at the NCCHD. During the same study period, we performed 12 (2.8%) LDLT operations in patients of <3 months of age. The potential donors were evaluated based on the results of liver function tests, blood group, human leukocyte antigen typing, anatomical variations, and graft volumetry (performed using 3-dimensional [3D] computed tomography [CT]). All of the patients received grafts from close family members.
OPERATION
The operative procedure has been previously described. (3, 4) From the perspective of the graft shape, if the LLS of the donor was bulky, and its maximum thickness was larger than the anteroposterior diameter in the recipient's abdominal cavity, which was identified as the length from the inside abdominal wall to the front of the vertebra on axial CT images, reducing the thickness of LLS graft was considered.
After isolating the donor left hepatic artery, hepatic duct, and portal branch, the hepatic parenchyma of the medial segment was transected at 5 mm to the right side of the falciform ligament without blood inflow occlusion or graft manipulation. The thickness of the LLSs of the donor grafts was reduced as necessary in situ. The determination of the transection plane for reduced LLS (in which the thickness of the LLS is reduced)-in which the main segment 2 and 3 branches were preserved-was made by intraoperative ultrasonography. In segment 2 monosegmentectomy, we confirmed that the entire length of the main left hepatic vein was preserved after the dissection of the Glissonian sheath in the umbilical portion of segment 3 on an intraoperative echogram. Thereafter, the ventral thickness of the LLS was resected and discarded following the ligation of the arteries, portal structures, and bile ducts of the upward segment without vascular occlusion and with the preservation of the main segment 3 branch.
Hepatic artery reconstruction was performed using microvascular techniques in all patients. Portal reconstruction was performed with interrupted sutures in the anterior wall, without the use of an interpositional vein graft. Biliary reconstruction was achieved using Roux-en-Y hepaticojejunostomy in all patients. Primary abdominal closure-with an anti-adhesion sheet in 8 later patients-was achieved in all patients without compression injury of the graft or respiratory failure. The discarded hepatic parenchyma was prepared for the "hepatocyte transplantation program," if informed consent was provided. (15) The initial immunosuppressive therapy consisted of tacrolimus and low-dose steroids, because ABO incompatibility did not have a significant impact in this age group. (16) All rejection episodes were diagnosed by liver biopsy. The measurements of cytomegalovirus (CMV)/EpsteinBarr virus (EBV) were performed by a quantitative polymerase chain reaction, which was performed weekly during hospitalization for the first 3 months after surgery, then monthly in an outpatient setting until 6 months after LT. (17, 18) Yoshihiro Hirata, and Akinari Fukuda are responsible for collection of the data. The results were compared with those of patients who underwent LDLT at 4-6 months of age (n 5 67) and 7-12 months of age (n 5 110) in the same study period.
The results were analyzed using the generalized Wilcoxon test. The actuarial patient and graft survival rates were calculated using the nonparametric KaplanMeier method compared with the Wilcoxon test results throughout the study. P values of <0.05 were considered to indicate statistical significance.
The present study was approved by the institutional review board (NCCHD-158), and informed consent was obtained for all of the patients.
Results
The overall rates of 10-year patient and graft survival in NCCHD were 92.9% and 90.3%, respectively. During the same study period, 12 (2.8%) LDLT procedures were performed in infants of <3 months of age. The donor and recipient profiles are shown in Table 1 . There were 3 male and 9 female patients. The median age was 38 days (range, 29-90 days). The median weight was 4.0 kg (range, 2.4-5.5 kg). The indications for transplantation included FHF (n 5 11; unknown origin, n 5 6; neonatal hemochromatosis, n 5 2; Echo virus type III, n 5 1; mitochondrial hepatopathy, n 5 1; and CMV hepatitis, n 5 1), and ornithine transcarbamylase deficiency (OTCD; n 5 1). With the exception of the OTCD patient, 11 patients were intensive care unit-bound under ventilation and apheresis (hemodiaphiltration and plasma exchange) therapy due to respiratory/renal impairment, hepatic encephalopathy, coagulopathy, and hyperammonemia-despite the provision of conventional medical treatments. The mean Pediatric EndStage Liver Disease (PELD) score was 32.7 6 12.6 (range, . The children had end-stage liver failure/metabolic decompensation and growth retardation, and could not wait to grow up and receive LDLT using a conventional LLS graft. Six patients received ABO-incompatible grafts. The median donor-recipient weight ratio was 14.1% (range, 9.9%-28.8%). A reduced LLS graft was used in 11 patients, and a segment 2 monosegment graft was used in 1 patient. The reduction in the thickness of the LLS grafts depended on the graft volume and the shape that was required, as previously reported. (3, 4, 19) The preoperative estimated graft-to-recipient weight ratio (GRWR) of the LLS on 3D CT volumetry was 7.77% 6 2.97% (range, 4.23%-15.62%). The discarded liver volume was 151.8 6 74.8 g (range, 48-325 g). As a result of the LLS reduction, the GRWR of the reduced LLS grafts was decreased to 3.42% 6 1.00% (range, 2.00%-4.73%). The median follow-up period was 45 months (range, 6-109 months). The duration and blood loss of the donor operation was 325.6 6 76.3 minutes (range, 206-469 minutes) and 246 6 212 mL (range, 50-710 mL). All of the donors were discharged within 9 days of surgery without any complications.
No vascular complications were observed among the current series of 12 LDLT patients. There were 2 biliary complications, biliary stricture in patient 3 and accidental segment 2 bile duct ligation during the donor operation in patient 10, which were successfully treated with radiological intervention (postoperative day 44) and reoperation (postoperative day 7), respectively. Patient 7 experienced right diaphragmic hernia on postoperative day 84, which was corrected with radical surgery. Acute cellular rejection was observed in 2 patients (patients 5 and 10), both of whom responded to steroid bolus injection therapy. The calcineurin inhibitor was converted from tacrolimus to cyclosporine in 4 patients, due to bone marrow suppression (patients 1 and 9) and seizure (patients 7 and 8). Patients 2, 3, 8, and 10 showed postoperative bloodstream infection with Stenotrophomonas maltophilia on postoperative day 21, Bacillis megatarum on day 31, Bacillus cereus on day 28, and Staphylococcus epidermidis on day 88, respectively. Patients 8 and 9 had preoperative CMV infection. Two patients had EBV infection (patient 2 on postoperative day 90 and patient 11 on day 60), and 6 patients had CMV infection (patient 4 on day 24, patient 5 on day 10, patient 6 on day 34, patient 9 on day 39, patient 11 on day 53, and patient 12 on day 43). Patient 7 died from respiratory failure due to respiratory syncytial virus infection on postoperative day 170-at the time, the patient had a normal liver function. The 10-year patient and graft survival rates in the LDLT patients of <3 months of age were both 90.9%. NOTE: Values are given as mean 6 SD (range) or n (%).
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The LDLT patients were divided according to age (<3 months; 4-6 months; and 7-12 months) and their results were compared. The patients who were <3 months of age had significantly higher PELD scores and tended to have a higher incidence of FHF as the original recipient liver disease. There were no statistically significant differences among the age groups with regard to the donor age, donor weight, operation profile, GRWR, surgical complications, or EBV infections. In the present series, the overall incidence of surgical complications in patients of <12 months of age were as follows: hepatic vein stenosis, 1.1%; hepatic artery thrombosis, 0%; portal vein stenosis/thrombosis, 4.8%/1.1%; and biliary leakage/stricture, 0.5%/ 4.8%. Patients who were <3 months of age tended to show a higher rate of biliary complications in comparison to the older infants.
Although the difference did not reach statistical significance, incidence of acute cellular rejection tended to be lower and the incidence of blood stream infection and CMV infection tended to be higher in recipients of <3 months of age. Moreover, there was a significant difference in the rate of conversion from tacrolimus to cyclosporine in the younger recipients ( Table 2 ). The overall cumulative 10-year patient/graft survival rates among the 3 groups were 90.9%/90.9%, 92.5%/90.9%, and 91.7%/82.6%, respectively. No significant difference was observed in the survival curves (Fig. 1A,B) .
Discussion
LT in neonates and young infants can be challenging due to a variety of factors. The few studies that have investigated LT in infants of <3 months of age have noted high rates of morbidity and mortality in comparison to older infants. It has been reported that patient and graft survival rates range from 55% to 60% and 43% to 50%, respectively. (13, 14) A recent United Network for Organ Sharing database analysis in infants weighing <5 kg showed improved 1-year patient and graft survival of 77.7% and 66.1% with recipient age a predictor of graft loss. (12) Because of improvements in perioperative management and surgical techniques, we achieved patient/graft survival rates of 90.9%/90.9% among the young infants in the present study. Although the former studies used grafts from deceased donors which could have greater wait-list mortality, with less cold ischemia, strict donor selection, and controlled procedures, LDLT might deliver fewer adverse outcomes than deceased donor LT, especially in this study population. (6) The disadvantages associated with the use of relatively large-for-size grafts include insufficient tissue oxygenation and graft compression, which results in a poor outcome. (20) Because small-sized grafts are difficult to obtain in deceased donor whole graft LT, LDLT with reduced LLS grafts may play a role as an alternative treatment in these young infants. (2, 3, 7) A total of 11 out of 12 recipients underwent LDLT due to FHF in the present study. It has been reported that the survival rates of pediatric patients with FHF were significantly lower in the short-term and longterm compared with the other indications despite relatively appropriate availability of donors compared with deceased LT.
(1) There remain ethical dilemmas regarding the potential donor candidates, such as the short amount of time for decision making for donations, evaluation for donor candidate, in addition to the LIVER TRANSPLANTATION, Vol. 23, No. 8, 2017 KASAHARA ET AL.
considerable constraints on potential donor candidates by other family members. (21) The potential donor safety is paramount in LDLT, the appropriate assessment including the risks should be discussed among all involved in the process.
There was a relatively high incidence of biliary stricture in the patients of <3 months of age. Monosegment grafts using segment 2 or 3 have recently been applied for small infants. (4) After the experience of biliary stricture and subsequent percutaneous interventional treatment, however, the reduction of the thickness of the LLS graft, with the preservation of the main segment 2 and 3 Glissonian sheath (rather than a single monosegment) has been increasingly adopted in our center, because of the ready accessibility for radiological interventional treatment in the event of biliary stricture. Moreover, the present report describes successful LDLT using reduced LLS grafts, which may provide better results and lower vascular complication rates.
It has been reported that the infants of <1 year of age experienced a higher rate of acute rejection and reducedsize liver grafts seemed to be at increased risk of acute rejection in an early series. (22, 23) Notably, the incidence of acute cellular rejection after LDLT appeared to be lower in patients of <3 months of age in comparison to older infants in the present study, whereas bloodstream and CMV infections were more common in younger infants. It is generally accepted that neonates and infants have increased susceptibility to bacterial and viral infections due to the immaturity of their immune systems. However, the mechanisms involved remain poorly understood. (24) There was a report demonstrating that the immunization of newborns against bacterial and viral infections might be hampered by ineffective CD81 T cell responses and thus the infants may have a high susceptibility to infections. (25) Although the patients of <3 months of age showed significantly higher PELD scores with life support management and may be immunocompromised prior to planned LDLT, these investigations allowed us to manage the patient without an escalation of immunosuppression after LDLT. There are 2 possible hypotheses to explain whyeven though less immunosuppression was provided-the acute cellular rejection was lower and the incidence of bacterial and viral infections was lower in younger infants. First, it might be due to an immature transitional state of immunity (given the ineffective CD81 T cell response), (25) or second, it could be due to the lack of a T helper 1 cell response and a bias toward T helper 2 immunity in younger infants. (26) Further immunological studies will be necessary to evaluate the precise mechanisms of acute rejection and infection in young infants.
It has been reported that graft and patient survival in pediatric LT patients who receive tacrolimus as primary immunosuppression are superior in comparison to those who receive cyclosporine. (27, 28) In the present study, however, 33.3% of the patients of <3 months of age required conversion from tacrolimus to cyclosporine as the baseline immunosuppressive therapy. This rate was significantly higher than that in older infants. In this study group, the clinical indications for conversion included neurological and hematological reasons. The incidence of neurotoxicity is reported to be higher in patients who receive tacrolimus. (29) The expression of cytochrome P450 (CYP) 3A7 at birth declines during the first 6 months of life because of the presence of unstable CYP450 polymorphisms in children, together with individual variability, whereas CYP3A4 reaches adult levels after 1 year of age. (30, 31) Moreover, serial intraindividual and interindividual variabilities of CYP3A activity have been reported. (32) On the basis of the lower rate of rejection, the tendency for an increased rate of infection, and the higher conversion rate in younger infants, the therapeutic immunosuppression levels and the type of immunosuppressant should be tailored for individual infants, especially in patients who require LDLT during the first 3 months of life.
Our study is associated with some limitations. As a single-center study, the number of patients and the follow-up period might have been too limited to draw definitive conclusions. To improve the understanding of the longterm suitability of LDLT in neonates and younger infants, it will be necessary to register and evaluate (on an ongoing basis) all patients who are considered for LT. Such a study is currently underway using the Japanese Liver Transplantation Society's mandatory registration database.
In summary, LDLT during the first 3 months of life appears to be a feasible option with excellent patient and graft survival in an experienced center. Longterm observation may be necessary to collect sufficient data to establish this treatment modality for young infants.
